Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BB 301

Next Previous
Drug Profile

BB 301

Alternative Names: AXO-AAV-OPMD-Axovant Sciences; BB-301; Pabparna™

Latest Information Update: 02 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Benitec Biopharma
  • Class Anti-inflammatories; Gene therapies; Small interfering RNA
  • Mechanism of Action Poly(A)-binding protein I expression inhibitors; Poly(A)-binding protein I replacements; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oculopharyngeal muscular dystrophy
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Oculopharyngeal muscular dystrophy

Most Recent Events

  • 19 Mar 2025 Efficacy and adverse events data from the phase Ib/IIa trial in Oculopharyngeal muscular dystrophy released by Benitec Biopharma
  • 14 Nov 2024 Interim efficacy and adverse events data from the phase Ib/IIa trial in Oculopharyngeal muscular dystrophy released by Benitec Biopharma
  • 15 Jul 2024 Updated interim adverse events and efficacy data from a phase Ib/IIa trial in Oculopharyngeal muscular dystrophy released by Benitec Biopharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top